GlassScriptPhysician profile
Herman Chavis
NPI 1386630564
$2,774.57
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $645 · 2021: $946 · 2022: $77.46 · 2023: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $483.68 | 2019-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $314.28 | 2019-2021 | |
| Novo Nordisk INC | $180.55 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.58 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.01 | 2019-2021 | |
| Mylan Specialty L.P. | $149.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $144.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $142.29 | 2019-2021 | |
| Abbvie INC. | $119.70 | 2021 | |
| Sunovion Pharmaceuticals INC. | $101.49 | 2019-2020 | |
| Pfizer INC. | $100.67 | 2019-2021 | |
| Amarin Pharma, INC. | $96.39 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $88.72 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $65.86 | 2019-2020 | |
| Lilly USA, LLC | $61.69 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.28 | 2019 | |
| Merck Sharp & Dohme LLC | $53.14 | 2020-2021 | |
| Esperion Therapeutics, INC. | $43.89 | 2021 | |
| Allergan, INC. | $40.96 | 2019 | |
| Hikma Pharmaceuticals USA | $36.36 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $29.55 | 2021 | |
| Ironwood Pharmaceuticals, INC | $27.99 | 2019 | |
| Eisai INC. | $26.40 | 2020 | |
| Amgen INC. | $25.85 | 2019 | |
| Biogen, INC. | $22.61 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.14 | 2021 | |
| Neotract INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Chavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.